The pharmacokinetics of ofloxacin were determined in six healthy volunteers after oral administration of 200 mg twice daily for 3.5 days. To study the pharmacokinetic behavior at the target site in bacterial infection of the skin, drug concentrations were determined in suction blister fluid (SBF) Ofloxacin is a fluorinated quinolone exhibiting a marked bactericidal effect by inhibiting DNA gyrase (13, 21). Ofloxacin is active against a wide spectrum of microorganisms, including gram-positive bacteria (11,23, 24). Moreover, it is one of the first drugs allowing oral treatment of infections caused by Pseudomonas aeruginosa (4).Ofloxacin shows therapeutically valuable pharmacokinetic properties such as a medium-range elimination half-life, almost complete bioavailability, negligible metabolism, and predominant renal excretion (9, 11).Since the target sites of antibiotics are predominantly located in the tissues, suitable tissue penetration is also mandatory. Lockley et al. (8) determined ofloxacin cantharides blister fluid (CBF) levels after a single oral dose of 600 mg. Kalager and co-workers (6) used the suction blister method to compare tissue levels in the fasting and nonfasting state (ofloxacin, 300 mg orally).In general, however, ofloxacin is not administered as a single dose but is administered repeatedly for 7 to 10 days. Thus, ofloxacin levels in serum and blister fluid after repeated drug intake are of particular interest. It was the aim of this study to compare ofloxacin levels in the fluids of noninflamed tissues (suction blister fluid [SBF]) (7,20) of an allergy to quinolone carboxylic acids. The study protocol was approved by the local ethics committee, and written informed consent was obtained from each volunteer. During the investigation period, the intake of other drugs and the ingestion of alcohol or caffeine were not allowed.